Gilead Sciences (GILD) Net Income towards Common Stockholders (2009 - 2026)
Gilead Sciences (GILD) recorded Net Income towards Common Stockholders of -$10.5 billion in Q2 2026, compared with $1.96 billion a year earlier.
Powered by 
Analysis
Gilead Sciences (GILD) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
On a TTM basis, Gilead Sciences' Net Income towards Common Stockholders came in at -$3.24 billion as of Jun 30, 2026; for FY2025, it was $8.51 billion.
- Annual Net Income towards Common Stockholders has a five-year compound annual growth rate of 133.3% (FY2020 to FY2025).
- Across earlier years, Net Income towards Common Stockholders came in at $480 million in FY2024 (-91.5%), $5.67 billion in FY2023 (+23.4%), $4.59 billion in FY2022 (-26.2%) and $6.23 billion in FY2021.
- The Q2 2026 figure is the lowest quarterly Net Income towards Common Stockholders in data going back to Q1 2009.
- On a year-over-year basis, Net Income towards Common Stockholders rose in five of the last six quarters, with growth averaging 37.2%.
- Peak year-over-year performance for Net Income towards Common Stockholders in the last five years was growth of 620.0% in Q3 2021, against a decline of 98.9% in Q1 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $2.02 billion (Q1 2026), $2.18 billion (Q4 2025) and $3.05 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Vertex Pharmaceuticals | 126.70 Bn | 98.70 Bn | 2.84 Bn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.50 Bn |
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.18 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.61 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.43 Bn |
| Sep 30, 2023 | 2.18 Bn |
| Jun 30, 2023 | 1.05 Bn |
| Mar 31, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.64 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 19.00 Mn |
| Dec 31, 2021 | 382.00 Mn |
| Sep 30, 2021 | 2.59 Bn |
API Access
Gilead Sciences Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=GILD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "GILD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=GILD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();